NCT04426890View on ClinicalTrials.gov

To Compare Efficacy and Safety of CT-P39 and EU-approved Xolair in Patients With Chronic Spontaneous Urticaria

PHASE3CompletedINTERVENTIONAL
Enrollment

634

Participants

Timeline

Start Date

December 9, 2020

Primary Completion Date

October 21, 2022

Study Completion Date

April 27, 2023

Conditions
Chronic Spontaneous Urticaria
Interventions
BIOLOGICAL

CT-P39

Prefilled syringe (PFS) of 1 mL solution

BIOLOGICAL

EU-approved Xolair

Prefilled syringe (PFS) of 1 mL solution

Trial Locations (1)

Unknown

Klinika Ambroziak ESTEDERM, Warsaw

Sponsors

Lead Sponsor

Celltrion
All Listed Sponsors
lead

Celltrion

INDUSTRY

NCT04426890 - To Compare Efficacy and Safety of CT-P39 and EU-approved Xolair in Patients With Chronic Spontaneous Urticaria | Biotech Hunter | Biotech Hunter